Northwest Biotherapeutics (NWBO) Accounts Payables (2010 - 2026)

Northwest Biotherapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $31.6 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 52.22% year-over-year to $31.6 million; the TTM figure through Mar 2026 stood at $31.6 million (up 52.22% YoY), while the FY2025 annual figure was $30.8 million, up 81.6% from the prior year.
• Accounts Payables for Q1 2026 stood at $31.6 million, up from $30.8 million in the prior quarter.
• The five-year high for Accounts Payables was $31.6 million in Q1 2026, with the low at $7.7 million in Q1 2022.
• The 5-year median for Accounts Payables is $15.1 million (2024), against an average of $16.5 million.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables retreated 11.15% in 2022, then surged 81.6% in 2025.
• Northwest Biotherapeutics' Accounts Payables stood at $10.7 million in 2022, then decreased by 4.15% to $10.2 million in 2023, then surged by 65.65% to $17.0 million in 2024, then soared by 81.6% to $30.8 million in 2025, then advanced by 2.49% to $31.6 million in 2026.
• Business Quant data shows NWBO's Accounts Payables at $31.6 million in Q1 2026, $30.8 million in Q4 2025, and $26.9 million in Q3 2025.